Treatment and Survival in Advanced Non-Small Cell Lung Cancer, Urothelial, Ovarian, Gastric and Kidney Cancer: A Nationwide Comprehensive Evaluation

References

• EscudierB, PortaC, SchmidingerM, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v58–v68. doi:10.1093/annonc/mdw32827664262
   PubMed Web of Science ®Google Scholar
• ReckM, PopatS, ReinmuthN, et al. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25:iii27–39. doi:10.1093/annonc/mdu19925115305
   PubMed Web of Science ®Google Scholar
• da SilvaJL, Dos SantosALS, NunesNCC, et al. Cancer immunotherapy: the art of targeting the tumor immune microenvironment. Cancer Chemother Pharmacol. 2019;84(2):227–240. doi:10.1007/s00280-019-03894-331240384
   PubMed Web of Science ®Google Scholar
• PostowMA, SidlowR, HellmannMD. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. N Engl J Med. 2018;378(2):158–168. doi:10.1056/NEJMra170348129320654
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. New Treatment for Advanced Melanoma [Press Release]. European Medicines Agency; 2015.
   Google Scholar
• BilginB, SendurMAN, HizalM, YalcinB. An update on immunotherapy options for urothelial cancer. Expert Opin Biol Ther. 2019;19(12):1265–1274. doi:10.1080/14712598.2019.166797531518156
   PubMed Web of Science ®Google Scholar
• KonoK, NakajimaS, MimuraK. Current status of immune checkpoint inhibitors for gastric cancer. Gastric Cancer. 2020;23(4):565–578. doi:10.1007/s10120-020-01090-432468420
   PubMed Web of Science ®Google Scholar
• Fashoyin-AjeL, DonoghueM, ChenH, et al. FDA Approval Summary: pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD-L1. Oncologist. 2019;24(1):103–109. doi:10.1634/theoncologist.2018-022130120163
   PubMed Web of Science ®Google Scholar
• TangJ, YuJX, Hubbard-LuceyVM, NeftelinovST, HodgeJP, LinY. Trial watch: the clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors. Nat Rev Drug Discov. 2018;17(12):854–855. doi:10.1038/nrd.2018.21030482962
   PubMed Web of Science ®Google Scholar
• RashdanS, GerberDE. Immunotherapy for non-small cell lung cancer: from clinical trials to real-world practice. Transl Lung Cancer Res. 2019;8(3):202–207. doi:10.21037/tlcr.2018.09.1531367533
   PubMed Web of Science ®Google Scholar
• SchmidtM, SchmidtSAJ, AdelborgK, et al. The Danish health care system and epidemiological research: from health care contacts to database records. Clin Epidemiol. 2019;11:563–591. doi:10.2147/CLEP.S17908331372058
   PubMed Web of Science ®Google Scholar
• GjerstorffML. The Danish Cancer Registry. Scand J Public Health. 2011;39(7 Suppl):42–45. doi:10.1177/140349481039356221775350
   PubMed Web of Science ®Google Scholar
• SchmidtM, SchmidtSA, SandegaardJL, EhrensteinV, PedersenL, SorensenHT. The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol. 2015;7:449–490. doi:10.2147/CLEP.S9112526604824
   PubMed Web of Science ®Google Scholar
• SchmidtM, PedersenL, SorensenHT. The Danish Civil Registration System as a tool in epidemiology. Eur J Epidemiol. 2014;29(8):541–549. doi:10.1007/s10654-014-9930-324965263
   PubMed Web of Science ®Google Scholar
• MainzJ, HessMH, JohnsenSP. The Danish unique personal identifier and the Danish Civil Registration System as a tool for research and quality improvement. Int j Quality Health Care. 2019;31(9):717–720.
   Web of Science ®Google Scholar
• ComptonCC, ByrdDR, Garcia-AguilarJ, KurtzmanSH, OlawaiyeA, WashingtonMK. AJCC Cancer Staging Atlas. New York: Springer; 2012.
   Google Scholar
• WitjesJA, BruinsHM, CathomasR, et al. EAU Guidelines on Muscle-Invasive and Metastatic Bladder Cancer. Arnhem, The Netherlands: EAU Guidelines Office; 2021.
   Google Scholar
• CharlsonME, PompeiP, AlesKL, MacKenzieCR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383. doi:10.1016/0021-9681(87)90171-83558716
   PubMedGoogle Scholar
• BjerregaardB, LarsenOB. The Danish Pathology Register. Scand J Public Health. 2011;39(7 Suppl):72–74. doi:10.1177/140349481039356321775357
   PubMed Web of Science ®Google Scholar
• ErichsenR, LashTL, Hamilton-DutoitSJ, BjerregaardB, VybergM, PedersenL. Existing data sources for clinical epidemiology: the Danish National Pathology Registry and Data Bank. Clin Epidemiol. 2010;2:51–56. doi:10.2147/CLEP.S990820865103
   PubMedGoogle Scholar
• KaplanEL, MeierP. Nonparametric Estimation from Incomplete Observations. J Am Stat Assoc. 1958;53(282):457–481. doi:10.1080/01621459.1958.10501452
   Web of Science ®Google Scholar
• BroeMO, JensenPB, MattssonTO, PottegardA. Validity of Antineoplastic Procedure Codes in the Danish National Patient Registry: the Case of Colorectal Cancer. Epidemiology. 2020;31(4):599–603. doi:10.1097/EDE.000000000000120832483069
   PubMed Web of Science ®Google Scholar
• LundJL, FroslevT, DeleuranT, et al. Validity of the Danish National Registry of Patients for chemotherapy reporting among colorectal cancer patients is high. Clin Epidemiol. 2013;5:327–334. doi:10.2147/CLEP.S4977324039450
   PubMedGoogle Scholar
• PedersenSA, SchmidtSAJ, KlausenS, et al. Melanoma of the Skin in the Danish Cancer Registry and the Danish Melanoma Database: a Validation Study. Epidemiology. 2018;29(3):442–447. doi:10.1097/EDE.000000000000080229337844
   PubMed Web of Science ®Google Scholar
• DeleuranT, SogaardM, FroslevT, et al. Completeness of TNM staging of small-cell and non-small-cell lung cancer in the Danish cancer registry, 2004–2009. Clin Epidemiol. 2012;4(Suppl 2):39–44. doi:10.2147/CLEP.S3331522936855
   PubMedGoogle Scholar
• de Alencar Camara VieiraFM, VictorinoA. Treatment Patterns Among Patients with Metastatic and/or Unresectable Gastric Cancer in Brazil. J Gastrointest Cancer. 2019;50(4):780–793. doi:10.1007/s12029-018-0145-930078125
   PubMed Web of Science ®Google Scholar
• JessmonP, BoulangerT, ZhouW, PatwardhanP. Epidemiology and treatment patterns of epithelial ovarian cancer. Expert Rev Anticancer Ther. 2017;17(5):427–437. doi:10.1080/14737140.2017.129957528277806
   PubMed Web of Science ®Google Scholar
• PalS, GongJ, MhatreSK, et al. Real-world treatment patterns and adverse events in metastatic renal cell carcinoma from a large US claims database. BMC Cancer. 2019;19(1):548. doi:10.1186/s12885-019-5716-z31174493
   PubMed Web of Science ®Google Scholar
• HaradaK, NozawaM, UemuraM, et al. Treatment patterns and outcomes in patients with unresectable or metastatic renal cell carcinoma in Japan. Int J Urol. 2019;26(2):202–210. doi:10.1111/iju.1383030345560
   PubMed Web of Science ®Google Scholar
• WagstaffJ, JonesR, HawkinsR, et al. Treatment patterns and clinical outcomes in patients with renal cell carcinoma in the UK: insights from the RECCORD registry. Ann Oncol. 2016;27(1):159–165. doi:10.1093/annonc/mdv50426489444
   PubMed Web of Science ®Google Scholar
• SimeoneJC, NordstromBL, PatelK, KleinAB. Treatment patterns and overall survival in metastatic non-small-cell lung cancer in a real-world, US setting. Future Oncol. 2019;15(30):3491–3502. doi:10.2217/fon-2019-034831497994
   PubMed Web of Science ®Google Scholar
• Om KRIS - Koordineringsrådet for ibrugtagning af sygehusmedicin. Available form:https://www.regioner.dk/kris/om-kris. Accessed 9 21, 2020.
   Google Scholar
• Om os. Medicinraadet.DK. Available form:https://medicinraadet.dk/om-os. Accessed 9 21, 2020.
   Google Scholar
• RichtersA, MehraN, MeijerRP, et al. Utilization of systemic treatment for metastatic bladder cancer in everyday practice: results of a nation-wide population-based cohort study. Cancer Treat Res Commun. 2020;25:100266. doi:10.1016/j.ctarc.2020.10026633316557
   PubMedGoogle Scholar
• WardMM, UllrichF, MatthewsK, et al. Who does not receive treatment for cancer?J Oncol Pract. 2013;9(1):20–26. doi:10.1200/JOP.2012.00082923633967
   PubMedGoogle Scholar
• JiangY, ChenM, NieH, YuanY. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations. Hum Vaccin Immunother. 2019;15(5):1111–1122. doi:10.1080/21645515.2019.157189230888929
   PubMed Web of Science ®Google Scholar
• JumeauR, VilotteF, DurhamAD, OzsahinEM. Current landscape of palliative radiotherapy for non-small-cell lung cancer. Transl Lung Cancer Res. 2019;8(Suppl 2):S192–S201. doi:10.21037/tlcr.2019.08.1031673524
   PubMed Web of Science ®Google Scholar